Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $66.22M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.07M
Average 1.40M
Returns on capital
Atara Biotherapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-84.9%
avg -184.8%
ROIC
222.7%
avg -32.4%
ROA
161.5%
avg -178.8%
Analysis
ROIC is currently the strongest return metric at 222.7% versus its period average of -32.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Anhco Nguyen | President, Chief Executive Officer & Director | USD 1.07M | 53 | 132.78K | 1.47% |
Alex Chapman | Vice President of Corporate Communications & Investor Relations | — | — | — | — |
Jim Sesic | Senior Vice President of Regulatory Affairs | — | — | — | — |
Kevin G. Sarney | Interim Chief Financial Officer | — | 61 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$5.74M
Sells
13
$3.79M
Net Transaction Value
+$1.95M
Net buying
Most Active
Nguyen AnhCo
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 4, 26Sep 4, 2026 | Cherry Brian N Direct | Buy | $1M$999,993.60 |
| Aug 17, 26Aug 17, 2026 | Nguyen AnhCo Direct | Sell | $40.9K$40,882.74 |
| May 18, 26May 18, 2026 | Nguyen AnhCo Direct | Sell | $47.8K$47,844.56 |
| May 18, 26May 18, 2026 | Grant-Huerta Yanina Direct | Sell | $22K$22,036.44 |
| May 7, 26May 7, 2026 | Panacea Innovation Ltd Indirect | Sell | $3.2M$3,165,020.99 |
| May 7, 26May 7, 2026 | EcoR1 Capital, LLC Indirect | Buy | $4.7M$4,744,255.45 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $121.8$121.85 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $8.1K$8,144.84 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $1.9K$1,915.91 |
| Mar 2, 26Mar 2, 2026 | Grant-Huerta Yanina Direct | Sell | $508.3$508.30 |
1–10 of 15
Summary
Insiders reported 2 buys worth $5.74M and 13 sells worth $3.79M over the last 12 months. That adds up to net buying of $1.95M. Nguyen AnhCo was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +1.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +23.9% | -5.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +1.5% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +6.5% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +23.9% over three years. Forward estimates point to EBIT at +6.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Atara Biotherapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ATRA's management, answered from reported figures.
Who manages ATRA?
Atara Biotherapeutics, Inc. (ATRA) lists 4 active executives. The top listed executive is Alex Chapman, Vice President of Corporate Communications & Investor Relations.
Are ATRA insiders buying or selling?
Recent insider activity shows net selling of $10.67M.
Continue the stock analysis
Jump to another research area for this company.